Modulation of death receptor pathways in oncology

Drugs of Today

Volumn 39, Issue SUPPL. C, 2003, Pages 95-109

  De Vries, E G E ^a   Timmer, T ^a   Mulder N H , ^a   Van Geelen, C M M ^a   Van Der Graaf, W T A ^a   Spierings, D C J ^a   De Hooge, M N ^a   Gietema, J A ^a   De Jong, S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9 INHIBITOR; CYTOTOXIC AGENT; DEATH RECEPTOR; DOCETAXEL; DOXORUBICIN; ENZYME INHIBITOR; ETANERCEPT; FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; INDOMETACIN; INFLIXIMAB; INTERFERON; MELPHALAN; MEMBRANE RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; RECEPTOR ANTIBODY; RECOMBINANT FAS LIGAND; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR; SALICYLIC ACID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ZINC;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL MEMBRANE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DNA DAMAGE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; HUMAN; HYPOTENSION; LIMB; LIVER CELL; LIVER TOXICITY; NONHUMAN; PHENOMENOLOGY; SARCOMA; SEPSIS;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0345098552     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (87)

1. De Jong, S., Timmer, T., Heijenbrok, F.J., de Vries, E.G. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 2001, 20: 51-6.
2. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2: 420-30.
3. Sleijfer S., Asschert, J.G., Timmer-Bosscha, H., Mulder, N.H. Enhanced sensitivity to tumor necrosis factor-alpha in doxorubicin-resistant tumor cell lines due to down-regulated c-erbB2. Int J Cancer 1998, 77: 101-6.
4. Walther, W., Stein, U. Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: Increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 1994, 120: 471-8.
5. Stein, U., Walther, W., Laurencot, C.M., Scheffer, G.L., Scheper, R.J., Shoemaker, R.H. Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst 1997, 89: 807-13.
6. Aderka, D., Sorkine, P., Abu-Abid, S. et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest 1998, 101: 650-9.
7. Sella, A., Aggarwal, B.B., Kilbourn, R.G., Bui, C.A., Zukiwski, A.A., Logothetis, C.J. Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. Cancer Biother 1995, 10: 225-35.
8. Curnis, F., Sacchi, A., Corti, A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002, 110: 475-82.
9. Stoelcker, B., Ruhland, B., Hehlgans, T., Bluethmann, H., Luther, T., Mannel, D.N. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 2000, 156: 1171-6.
10. Creagan, E.T., Kovach, J.S., Moertel, C.G., Frytak, S., Kvols, L.K. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 1988, 62: 2467-71.
11. Jakubowski, A.A., Casper, E.S., Gabrilove, J.L., Templeton, M.A., Sherwin, S.A., Oettgen, H.F. Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1989, 7: 298-303.
12. Creaven, P.J., Brenner, D.E., Cowens, J.W. et al. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 1989, 23: 186-91.
13. Gamm, H., Lindemann, A., Mertelsmann, R., Herrmann, F. Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer 1991, 27: 856-63.
14. Furman, W.L., Strother, D., McClain, K., Bell, B., Leventhal, B., Pratt, C.B. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: A Pediatric Oncology Group study. J Clin Oncol 1993, 11: 2205-10.
15. Eskander, E.D., Harvey, H.A., Givant, E., Lipton, A. Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2. Am J Clin Oncol 1997, 20: 511-4.
16. Seibel, N.L., Dinndorf, P.A., Bauer, M., Sondel, P.M., Hammond, G.D., Reaman, G.H. Phase I study of tumor necrosis factor-alpha and actinomycin D in pediatric patients with cancer: A Children's Cancer Group study. J Immunother Emphasis Tumor Immunol 1994, 16: 125-31.
17. Lejeune, F.J., Kroon, B.B., Di Filippo, F. et al. Isolated limb perfusion: The European experience. Surg Oncol Clin N Am 2001, 10: 821-32.
18. Lejeune, F.J. Clinical use of TNF revisited: Improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 2002, 110: 433-5.
19. Ten Hagen, T.L., Seynhaeve, A.L., van Tiel, S.T., Ruiter, D.J., Eggermont, A.M. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil®) in soft tissue sarcoma-bearing rats. Int J Cancer 2002, 97: 115-20.
20. Kianmanesh, A., Hackett, N.R., Lee, J.M., Kikuchi, T., Korst, R.J., Crystal, R.G. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther 2001, 12: 2035-49.
21. Tsimberidou, A.M., Giles, F.J. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2002, 2: 277-86.
22. Shanahan, J.C., St. Clair, W. Tumor necrosis factor-alpha blockade: A novel therapy for rheumatic disease. Clin Immunol 2002, 103: 231-42.
23. Van Deventer, S.J. Anti-tumour necrosis factor therapy in Crohn's disease: Where are we now? Gut 2002, 51: 362-3.
24. Maciejewski, J.P., Ristiano, A.M., Sloand, E.M. et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002, 117: 119-26.
25. Deeg, H.J., Gotlib, J., Beckham, C. et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelo-dysplastic syndrome: A pilot study. Leukemia 2002, 16: 162-4.
26. Tsimberidou, A.M., Thomas, D., O'Brien, S. et al. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol 2002, 50: 237-42.
27. Teshima, T., Ordemann, R., Reddy, P. et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8: 575-81.
28. Chiang, K.Y., Abhyankar, S., Bridges, K., Godder, K., Henslee-Downey, J.P. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002, 73: 665-7.
29. National Institutes of Health. Docetaxel with or without infliximab in treating weight loss, loss of appetite, and fatigue in patients with advanced non-small cell lung cancer. http://www.clinicaltrials.gov/ct/gui/show/NCTOOO40885?order=5.
30. Suda, T., Takahashi, T., Golstein, P., Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75: 1169-78.
31. Nagata, S., Golstein, P. The Fas death factor. Science 1995, 267: 1449-56.
32. Itoh, N., Yonehara, S., Ishii, A. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66: 233-43.
33. Trauth, B.C., Klas, C., Peters, A.M. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245: 301-5.
34. Chinnaiyan, A.M., O'Rourke, K., Tewari, M., Dixit, V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81: 505-12.
35. Kischkel, F.C., Hellbardt, S., Behrmann, I. et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995, 14: 5579-88.
36. Tanaka, M., Suda, T., Haze, K. et al. Fas ligand in humn serum. Nat Med 1996, 2: 317-22.
37. Arase, H., Arase, N., Saito, T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995, 181: 1235-8.
38. Rouvier, E., Luciani, M.F., Golstein, P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993, 177: 195-200.
39. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., Duke, R.C. A role for CD95 ligand in preventing graft rejection. Nature 1995, 377: 630-2.
40. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., Ferguson, T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270: 1189-92.
41. Hunt, J.S., Vassmer, D., Ferguson, T.A., Miller, L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997, 158: 4122-8.
42. Ju, S.T., Matsui, K., Ozdemirli, M. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction. Int Rev Immunol 1999, 18: 485-513.
43. Weller, M., Frei, K., Groscurth, P., Krammer, P.H., Yonekawa, Y., Fontana, A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994, 94: 954-64.
44. Weller, M., Malipiero, U., Aguzzi, A., Reed, J.C., Fontana, A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995, 95: 2633-43.
45. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M. et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364: 806-9.
46. Rensing-Ehl, A., Frei, K., Flury, R. et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995, 25: 2253-8.
47. Morelli, A.E., Larregina, A.T., Smith-Arica, J. et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol 1999, 80: 571-83.
48. Aoki, K., Akyurek, L.M., San, H. et al. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol Ther 2000, 1: 555-65.
49. Ozoren, N., Kim, K., Burns, T.F., Dicker, D.T., Moscioni, A.D., el Deiry, W.S. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000, 60: 6259-65.
50. Wielockx, B., Lannoy, K., Shapiro, S.D. et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 2001, 7: 1202-8.
51. Keane, M.M., Ettenberg, S.A., Lowrey, G.A., Russell, E.K., Lipkowitz, S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1995, 56: 4791-8.
52. Xu, X., Fu, X.Y., Plate, J., Chong, A.S. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: Requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 1998, 58: 2832-7.
53. Ossina, N.K., Cannas, A., Powers, V.C. et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997, 272: 16351-7.
54. Schwartzberg, L.S., Petak, I., Stewart, C. et al. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: Phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Clin Cancer Res 2002, 8: 2488-98.
55. Han, Z., Pantazis, P., Wyche, J.H., Kouttab, N., Kidd, V.J., Hendrickson, E.A.A. Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line. J Biol Chem 2001, 276: 38748-54.
56. Nzeako, U.C., Guicciardi, M.E., Yoon, J.H., Bronk, S.F., Gores, G.J. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 2002, 35: 552-9.
57. Giardina, C., Boulares, H., Inan, M.S. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: The role of reactive oxygen species. Biochim Biophys Acta 1999, 1448: 425-38.
58. Wajant, H., Pfizenmaier, K., Scheurich, P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002, 7: 449-59.
59. Nagane, M., Huang, H.J.S., Cavenee, W.K. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001, 6: 191-7.
60. Lawrence, D., Shahrokh, Z., Marsters, S. et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001, 7: 383-5.
61. Ashkenazi, A., Pai, R.C., Fong, S. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104: 155-62.
62. Pollack, I.F., Erff, M., Ashkenazi, A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001, 7: 1362-9.
63. Walczak, H., Miller, R.E., Ariail, K. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5: 157-63.
64. Ashkenazi, A., Pai, R.C., Fong, S. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104: 155-62.
65. Kelley, S.K., Harris, L.A., Xie, D. et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001, 299: 31-8.
66. Liabakk, N.B., Sundan, A., Torp, S., Aukrust, P., Froland, S.S., Espevik, T. Development, characterization and use of monoclonal antibodies against sTRAIL: Measurement of sTRAIL by ELISA. J Immunol Methods 2002, 259: 119-28.
67. Salcedo, Alderson, Basu et al. TRM-1, a fully human TRAIL-R1 agonistic monoclonal antibody, displays in vitro and in vivo anti-tumor activity. Proc Amer Assoc Cancer Res 2002, Abst 4240.
68. Ichikawa, K., Liu, W., Zhao, L. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001, 7: 954-60.
69. Sheridan, J.P., Marsters, S.A., Pitti, R.M. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277: 818-21.
70. Pan, G., O'Rourke, K., Chinnaiyan, A.M. et al. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276: 111-3.
71. Griffith, T.S., Chin, W.A., Jackson, G.C., Lynch, D.H., Kubin, M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998, 161: 2833-40.
72. Griffith, T.S., Rauch, C.T., Smolak, P.J. et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999, 162: 2597-605.
73. Held, J., Schulze-Osthoff, K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Update 2001, 4: 243-52.
74. Nguyen, T., Zhang, X.D., Hersey, P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 2001, 7: 966s-73s.
75. Ashkenazi, A., Dixit, V.M. Death receptors: Signaling and modulation. Science 1998, 281: 1305-8.
76. Mitelman, F., Mertens, F., Johansson, B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 1997, 15: 417-74.
77. Ozoren, N., Fisher, M.J., Kim, K. et al. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 2000, 16: 917-25.
78. Kim, K., Fisher, M.J., Xu, S.Q., El Deiry, W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000, 6: 335-46.
79. Pai, S.I., Wu, G.S., Ozoren, N. et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998, 58: 3513-8.
80. Shin, M.S., Kim, H.S., Lee, S.H. et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001, 61: 4942-6.
81. Bin, L., Li, X., Xu, L.G., Shu, H.B. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 2002, 510: 37-40.
82. Burns, T.F., El Deiry, W.S. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001, 276: 37879-86.
83. Zhang, X.D., Franco, A., Myers, K., Gray, C., Nguyen, T., Hersey, P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999, 59: 2747-53.
84. LeBlanc, H., Lawrence, D., Varfolomeev, E. et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002, 8: 274-81.
85. Barkett, M., Gilmore, T.D. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999, 18: 6910-24.
86. Ravi, R., Bedi, G.C., Engstrom, L.W. et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001, 3: 409-16.
87. Hu, W.H., Johnson, H., Shu, H.B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 1999, 274: 30603-10.